Isolated Systolic Hypertension in the Elderly and Very Elderly
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of long-term treatment of individually optimized doses of olmesartan
medoxomil compared to nitrendipine in elderly and very elderly patients with isolated
systolic hypertension. The study hypothesis is non-inferiority of olmesartan medoxomil
compared to nitrendipine in lowering mean sitting systolic blood pressure after 12 weeks of
treatment compared to baseline. The study duration is up to 32 weeks, including a 24-week
treatment period. After 12 weeks hydrochlorothiazide may be added to control blood pressure.
Efficacy and safety measurements are carried out at up to 15 visits during the trial period.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Europe, GmbH Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company